Back to: products

North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity

PrintEmail
Aug 2020 - 91 Pages - From $3,000
(Excel Data Sheet: $1,800)
Description

The report cover may be different from the image shown.

Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

North America influenza treatment market is expected to grow by 2.3% annually in the forecast period and reach $569.8 million by 2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment in the region.
Highlighted with 23 tables and 40 figures, this 91-page report “North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country.

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oseltamivir Phosphate
• Baloxavir Marboxil
• Peramivir
• Zanamivir
• Other Drugs

Based on Influenza Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Influenza A
• Influenza B
• Influenza C

Based on Administration Route, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oral Administration
• Other Administration Routes

Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Retail Pharmacy
• Hospital Pharmacy
• Clinics
• Online Stores

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc 
BioCryst Pharmaceuticals Inc. 
Biondvax 
Daiichi Sankyo Company 
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) 
GlaxoSmithKline Plc 
Mylan N.V 
Natco Pharma Limited 
Novartis AG 
Sanofi 
Seqirus 
Teva Pharmaceutical Industries Limited 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 5
1.1 Industry Definition and Research Scope 5
1.1.1 Industry Definition 5
1.1.2 Research Scope 6
1.2 Research Methodology 9
1.2.1 Overview of Market Research Methodology 9
1.2.2 Market Assumption 10
1.2.3 Secondary Data 10
1.2.4 Primary Data 10
1.2.5 Data Filtration and Model Design 12
1.2.6 Market Size/Share Estimation 13
1.2.7 Research Limitations 14
1.3 Executive Summary 15
2 Market Overview and Dynamics 17
2.1 Market Size and Forecast 17
2.1.1 Impact of COVID-19 on the Market 18
2.2 Major Growth Drivers 20
2.3 Market Restraints and Challenges 24
2.4 Emerging Opportunities and Market Trends 27
2.5 Porter’s Fiver Forces Analysis 31
3 Segmentation of North America Market by Product Type 35
3.1 Market Overview by Product Type 35
3.2 Oseltamivir Phosphate 37
3.3 Baloxavir Marboxil 38
3.4 Peramivir 39
3.5 Zanamivir 40
3.6 Other Drugs 41
4 Segmentation of North America Market by Influenza Type 42
4.1 Market Overview by Influenza Type 42
4.2 Influenza A 44
4.3 Influenza B 45
4.4 Influenza C 46
5 Segmentation of North America Market by Administration Route 47
5.1 Market Overview by Administration Route 47
5.2 Oral Administration 49
5.3 Other Administration Routes 50
6 Segmentation of North America Market by Distribution Channel 51
6.1 Market Overview by Distribution Channel 51
6.2 Retail Pharmacy 53
6.3 Hospital Pharmacy 54
6.4 Clinics 55
6.5 Online Stores 56
7 North America Market 2019-2030 by Country 57
7.1 Overview of North America Market 57
7.2 U.S. 60
7.3 Canada 64
7.4 Mexico 66
8 Competitive Landscape 68
8.1 Overview of Key Vendors 68
8.2 New Product Launch, Partnership, Investment, and M&A 71
8.3 Company Profiles 72
AstraZeneca Plc 72
BioCryst Pharmaceuticals Inc. 74
Biondvax 75
Daiichi Sankyo Company 76
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) 77
GlaxoSmithKline Plc 78
Mylan N.V 79
Natco Pharma Limited 80
Novartis AG 81
Sanofi 82
Seqirus 83
Teva Pharmaceutical Industries Limited 84
9 Investing in North America Market: Risk Assessment and Management 85
9.1 Risk Evaluation of North America Market 85
9.2 Critical Success Factors (CSFs) 88
Related Reports and Products 91

List of Tables:

Table 1.  Snapshot of North America Influenza Treatment Market, 2019-2030 16
Table 2.  Main Product Trends and Market Opportunities in North America Influenza Treatment Market 27
Table 3. North America Influenza Treatment Market by Product Type, 2019-2030, $ mn 35
Table 4. North America Influenza Treatment Market by Influenza Type, 2019-2030, $ mn 42
Table 5. North America Influenza Treatment Market by Administration Route, 2019-2030, $ mn 47
Table 6. North America Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn 51
Table 7. North America Influenza Treatment Market by Country, 2019-2030, $ mn 58
Table 8. U.S. Influenza Treatment Market by Product Type, 2019-2030, $ mn 62
Table 9. U.S. Influenza Treatment Market by Administration Route, 2019-2030, $ mn 62
Table 10. U.S. Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn 62
Table 11. Canada Influenza Treatment Market by Product Type, 2019-2030, $ mn 65
Table 12. Canada Influenza Treatment Market by Administration Route, 2019-2030, $ mn 65
Table 13. Canada Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn 65
Table 14. Mexico Influenza Treatment Market by Product Type, 2019-2030, $ mn 67
Table 15. Mexico Influenza Treatment Market by Administration Route, 2019-2030, $ mn 67
Table 16. Mexico Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn 67
Table 17. AstraZeneca Plc: Company Snapshot 72
Table 18. AstraZeneca Plc: Business Segmentation 72
Table 19. AstraZeneca Plc: Product Portfolio 73
Table 20. AstraZeneca Plc: Revenue, 2016-2018, $ mn 73
Table 21. AstraZeneca Plc: Recent Developments 73
Table 22.  Risk Evaluation for Investing in North America Market, 2019-2030 86
Table 23. Critical Success Factors and Key Takeaways 89

 


List of Figures:

Figure 1. Research Method Flow Chart 9
Figure 2. Breakdown of Primary Research 11
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 13
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 15
Figure 5. North America Influenza Treatment Market, 2019-2030, $ mn 17
Figure 6. Impact of COVID-19 on Business 18
Figure 7. Primary Drivers and Impact Factors of North America Influenza Treatment Market 20
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 23
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 23
Figure 10. Primary Restraints and Impact Factors of North America Influenza Treatment Market 24
Figure 11. Investment Opportunity Analysis 28
Figure 12. Porter’s Fiver Forces Analysis of North America Influenza Treatment Market 31
Figure 13. Breakdown of North America Influenza Treatment Market by Product Type, 2019-2030, % of Revenue 35
Figure 14. North America Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%) 36
Figure 15. North America Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn 37
Figure 16. North America Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn 38
Figure 17. North America Influenza Treatment Market: Peramivir, 2019-2030, $ mn 39
Figure 18. North America Influenza Treatment Market: Zanamivir, 2019-2030, $ mn 40
Figure 19. North America Influenza Treatment Market: Other Drugs, 2019-2030, $ mn 41
Figure 20. Breakdown of North America Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue 42
Figure 21. North America Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%) 43
Figure 22. North America Influenza Treatment Market: Influenza A, 2019-2030, $ mn 44
Figure 23. North America Influenza Treatment Market: Influenza B, 2019-2030, $ mn 45
Figure 24. North America Influenza Treatment Market: Influenza C, 2019-2030, $ mn 46
Figure 25. Breakdown of North America Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue 47
Figure 26. North America Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%) 48
Figure 27. North America Influenza Treatment Market: Oral Administration, 2019-2030, $ mn 49
Figure 28. North America Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn 50
Figure 29. Breakdown of North America Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue 51
Figure 30. North America Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%) 52
Figure 31. North America Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn 53
Figure 32. North America Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn 54
Figure 33. North America Influenza Treatment Market: Clinics, 2019-2030, $ mn 55
Figure 34. North America Influenza Treatment Market: Online Stores, 2019-2030, $ mn 56
Figure 35. Breakdown of North America Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 58
Figure 36. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 59
Figure 37. U.S. Influenza Treatment Market, 2019-2030, $ mn 61
Figure 38. Canada Influenza Treatment Market, 2019-2030, $ mn 64
Figure 39.  Influenza Treatment Market in Mexico, 2015-2030, $ mn 66
Figure 40. Growth Stage of North America Influenza Treatment Industry over the Forecast Period 68

 

Reviews

There are yet no reviews for this product.